Actavis, Inc. (NYSE:ACT)

CAPS Rating: 4 out of 5

The Company is engaged in the development, manufacture, marketing, sale and distribution of brand and off-patent pharmaceutical products.

Results 1 - 20 of 39 : 1 2 Next »

Recs

0
Member Avatar DrGoldin (99.77) Submitted: 5/8/2015 8:17:35 PM : Outperform Start Price: $305.77 ACT Score: -1.45

Each time I think this company's earnings can't keep growing, they prove me wrong, and I'm salivating at the recent sell-off.

Recs

0
Member Avatar CellBlock9 (89.23) Submitted: 4/26/2015 11:03:34 AM : Outperform Start Price: $296.95 ACT Score: +1.82

mgk, 295.41

Recs

0
Member Avatar bartlettmi (74.07) Submitted: 4/22/2015 2:01:29 PM : Outperform Start Price: $294.84 ACT Score: +1.77

I believe in the bull case... Botox was a steal.

Recs

0
Member Avatar 23dluxe (33.97) Submitted: 4/22/2015 2:23:39 AM : Outperform Start Price: $294.62 ACT Score: +1.52

Obamacare

Recs

0
Member Avatar stocky5 (41.53) Submitted: 4/8/2015 2:25:45 PM : Outperform Start Price: $294.39 ACT Score: +0.63

Oversold and undervalued. Forward PEG is less than 1.0, and the company has beaten analysts earnings estimates in the last 2 quarters. ACT warrants a higher PE based on its growth, and analysts agree, raising price targets. The recent pullback in the stock is an excellent buying opportunity.

Recs

0
Member Avatar derbydog85 (32.34) Submitted: 3/17/2015 8:19:30 PM : Outperform Start Price: $308.50 ACT Score: -4.33

Botox use might be used for depression....Growth pharma company has great pipeline...Plenty of upside ahead.

Recs

0
Member Avatar zojo360 (69.27) Submitted: 3/7/2015 2:58:20 PM : Outperform Start Price: $295.29 ACT Score: +1.01

A key element to Actavis’ growth has been the so-called patent cliff, a period when many of the world’s best-selling drugs are losing patent protection. In fact, Actavis has specifically mentioned in the past the new generic introduction of drugs such as Suboxone, Lidoderm and Concerta as growth drivers.

The UBS price target for the stock is $333. The Thomson/First Call consensus price target is lower at $313.11. Shares closed Tuesday at $296.23.

Recs

0
Member Avatar benyboy (< 20) Submitted: 3/5/2015 9:23:55 AM : Outperform Start Price: $297.10 ACT Score: +0.96

John Paulson

Recs

0
Member Avatar pythonmonte (73.80) Submitted: 2/21/2015 8:46:54 PM : Outperform Start Price: $296.43 ACT Score: +1.34

I hears its one of the four horse men of the apolcospe yhe other 3 GILD,REGN,Clgn.

Recs

0
Member Avatar RugbyViking13 (88.81) Submitted: 9/23/2014 2:24:07 PM : Outperform Start Price: $242.77 ACT Score: +17.27

lexapro - you can never leave

Recs

0
Member Avatar tripleking (61.76) Submitted: 6/17/2014 10:21:35 AM : Outperform Start Price: $213.00 ACT Score: +32.62

good stock

Recs

0
Member Avatar Classical (63.78) Submitted: 3/28/2014 4:51:43 PM : Outperform Start Price: $204.27 ACT Score: +34.01

Excellent management, has not missed earnings since 2006 when the company was formally known as Watson. Growing bottom line organically and continues to cherry pick M&A that makes sense. Snaps up branded drugs coming off patent for its favorably large generic portfolio. This will be 100 billion dollar market cap if management continues its track record. Obama-care benefits this company directly because it generic line is so vast.

The founder ( Dr. Choi) started the company out of his garage!

Recs

1
Member Avatar naughtyguy (31.36) Submitted: 3/13/2014 10:43:49 AM : Underperform Start Price: $215.20 ACT Score: -26.77

34 billion market cap! You have got to be kidding!

Recs

0
Member Avatar DugdaleTiki (41.18) Submitted: 3/3/2014 9:27:18 AM : Outperform Start Price: $213.00 ACT Score: +26.79

2014 Sabrient Pick

Recs

0
Member Avatar StewpotDrew (56.63) Submitted: 2/3/2014 12:13:39 AM : Outperform Start Price: $190.00 ACT Score: +39.53

Drugs.

Recs

0
Member Avatar subsurfacemapper (48.63) Submitted: 1/22/2014 11:47:04 PM : Outperform Start Price: $186.18 ACT Score: +46.26

high RS in ibd and high comp

Recs

0
Member Avatar 1picks (88.75) Submitted: 1/13/2014 2:24:18 PM : Outperform Start Price: $182.72 ACT Score: +48.72

Sabrient

Recs

0
Member Avatar manirg (88.29) Submitted: 12/24/2013 12:28:45 PM : Outperform Start Price: $164.50 ACT Score: +67.23

Undervalued growth stock

Recs

0
Member Avatar chris293 (84.93) Submitted: 10/24/2013 5:49:57 PM : Underperform Start Price: $146.30 ACT Score: -85.06

Some of these stocks I just do not understand. A lot of negatives, for example a minus ROI, among others? O.K. they made 6 cents.

Recs

0
Member Avatar djtp54 (< 20) Submitted: 9/8/2013 2:58:01 PM : Outperform Start Price: $137.40 ACT Score: +91.81

bought the stock when it was Watson Pharma its been my best performer and i like how its been working

Results 1 - 20 of 39 : 1 2 Next »

Featured Broker Partners


Advertisement